Metoclopramide HCl Clinical Trials

Size	Price	Qty
50mg	USD 97
200mg	USD 197

Clinical Trials

Multiple clinical trials are currently investigating interventions for conditions such as post-operative nausea and vomiting, acute upper gastrointestinal bleeding, diabetic gastroparesis, brain injuries, and surgical treatment complications. Encompassing Phase 2, Phase 3, and non-applicable phase designs, these actively recruiting and unknown-status studies evaluate targeted outcomes including post-operative emesis prevention and endoscopic clarity. These initiatives are sponsored by a range of academic institutions, hospital systems, and industry partners.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05759481	Recruiting	Post-operative Nausea and Vomiting	Milton S. Hershey Medical Center	2024-02-01	Phase 2
NCT06297954	Recruiting	Upper Gastrointestinal Bleeding	Universidad Autonoma de Nuevo Leon	2023-03-16	Phase 3
NCT05832151	Recruiting	Diabetic Gastroparesis	CinDome Pharma Inc.	2023-03-27	Phase 2
NCT05008926	Recruiting	Brain Injuries	University Hospital Brest	2022-03-15	Phase 3
NCT04748133	Unknown status	Treatment Complication	Zagazig University	2021-02-20	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Metoclopramide HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Metoclopramide HCl selectively binds to and antagonizes dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, thereby blocking dopamine-mediated inhibition of smooth muscle motility and enhancing upper gastrointestinal cholinergic signaling. This inhibition promotes gastric emptying, increases lower esophageal sphincter tone, and suppresses emetic signal transduction, providing therapeutic efficacy in managing post-operative nausea and vomiting, endoscopic visualization in upper gastrointestinal bleeding, and diabetic gastroparesis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).